Exploring the Impact of Serum Growth Factors in the Pathogenesis of Acute and Chronic Myeloid Leukemia
DOI:
https://doi.org/10.22317/jcms.v11i1.1693Keywords:
Leukemia, Fibroblast Growth Factor 2, Vascular Endothelial Growth Factor A, Platelet-Derived Growth Factor, LeukocytesAbstract
Objective: The aim of this study is to assess the potential association between the amounts of serum growth factors and the risk of developing acute and chronic myeloid leukemia.
Methods: The research comprised 168 participants, aged between 21 and 69 of these, 52 were diagnosed with acute myeloid leukemia, while 71 had chronic myeloid leukemia from Hiwa Hospital in Sulaymaniyah. Moreover, 45 healthy individuals, matched for age and gender, were also recruited to act as controls in the study. The levels of Basic fibroblast growth factor, Insulin-like growth factor I, Vascular endothelial growth factor, Hepatocyte growth factor, Platelet-Derived Growth Factor and Transforming growth factor-β in the serum were evaluated using the sandwich enzyme-linked immunosorbent assay (ELISA) method, employing kits produced by RayBiotech company.
Results: Between the patient groups and the healthy control group, the mean values for the study parameters were compared using a one-way ANOVA. The serum levels of all mentioned growth factors showed significantly elevation in patients comparing to controls.
Conclusion: Serum Basic fibroblast growth factor and other growth factors might be a potential complementary biomarker for acute myeloid leukemia and chronic myeloid leukemia.
References
Dong Y, Shi O, Zeng Q, Lu X, Wang W, Li Y, Wang Q. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Experimental hematology & oncology. 2020 Dec;9:1-1.
Blackburn LM, Bender S, Brown S. Acute leukemia: diagnosis and treatment. InSeminars in oncology nursing 2019 Dec 1 (Vol. 35, No. 6, p. 150950). WB Saunders.
Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management. American Journal of Hematology. 2023 Mar;98(3):502-26.
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G. Genomic classification and prognosis in acute myeloid leukemia. New England Journal of Medicine. 2016 Jun 9;374(23):2209-21.
Premnath N, Madanat YF. Paradigm shift in the management of acute myeloid leukemia—approved options in 2023. Cancers. 2023 May 31;15(11):3002.
Rinaldi I, Winston K. Chronic myeloid leukemia, from pathophysiology to treatment-free remission: a narrative literature review. Journal of Blood Medicine. 2023 Dec 31:261-77.
Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. American journal of hematology. 2020 Jun;95(6):691-709.
Boiko AS, Mednova IA, Kornetova EG, Bokhan NA, Ivanova SA. Serum Growth Factors in Schizophrenia Patients. Current Issues in Molecular Biology. 2023 Apr 7;45(4):3291-301.
Isali I, Al-Sadawi MA, Qureshi A, Khalifa AO, Agrawal MK, Shukla S. Growth factors involve in cellular proliferation, differentiation and migration during prostate cancer metastasis. International journal of cell biology and physiology. 2019;2(1-2):1.
Ardizzone A, Bova V, Casili G, Repici A, Lanza M, Giuffrida R, Colarossi C, Mare M, Cuzzocrea S, Esposito E, Paterniti I. Role of basic fibroblast growth factor in cancer: biological activity, targeted therapies, and prognostic value. Cells. 2023 Mar 24;12(7):1002.
Parma L, Peters HA, Sluiter TJ, Simons KH, Lazzari P, de Vries MR, Quax PH. bFGF blockade reduces intraplaque angiogenesis and macrophage infiltration in atherosclerotic vein graft lesions in ApoE3* Leiden mice. Scientific reports. 2020 Sep 29;10(1):15968.
Steringer JP, Lange S, Čujová S, Šachl R, Poojari C, Lolicato F, Beutel O, Müller HM, Unger S, Coskun Ü, Honigmann A. Key steps in unconventional secretion of fibroblast growth factor 2 reconstituted with purified components. Elife. 2017 Jul 19;6:e28985.
Song MZ, Mao YM, Wu J, Pan HF, Ye QL. Increased circulating basic fibroblast growth factor levels in acute myeloid leukemia: a meta-analysis. Hematology. 2020 Jan 1;25(1):186-93.
Betzmann D, Döring M, Blumenstock G, Erdmann F, Grabow D, Lang P, Binder G. Impact of Serum Insulin-Like Growth Factor 1 on Hematopoietic Stem Cell Transplantation Outcome in Pediatric Cancer Patients. Transplantation and Cellular Therapy. 2022 Jul 1;28(7):355-e1.
Bailes J, Soloviev M. Insulin-like growth factor-1 (IGF-1) and its monitoring in medical diagnostic and in sports. Biomolecules. 2021 Feb 4;11(2):217.
Sawaf N, Saleh J. The role of insulin-like growth factor I (IGF-I) in treatment monitoring of acute lymphoblastic leukemia pediatric patients. Journal of Medical Oncology and Therapeutics. 2017;02(01).
Bokhari SM, Hamar P. Vascular endothelial growth factor-D (VEGF-D): An angiogenesis bypass in malignant tumors. International Journal of Molecular Sciences. 2023 Aug 28;24(17):13317.
Elebiyo TC, Rotimi D, Evbuomwan IO, Maimako RF, Iyobhebhe M, Ojo OA, Oluba OM, Adeyemi OS. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy. Cancer Treatment and Research Communications. 2022 Jan 1;32:100620.
Sopo M, Anttila M, Hämäläinen K, Kivelä A, Ylä-Herttuala S, Kosma VM, Keski-Nisula L, Sallinen H. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer. BMC cancer. 2019 Dec;19:1-2.
Orozco-Ureña LI, Villegas LE, Morales FG, Castorena VI, Flores CC, Colín-Ruiz JM, Aparicio-Ozores G, Moreno-Galván M. Monitoring vascular endothelial growth factor-a levels during follow-up after hematopoietic stem cell transplantation in pediatric patients at a Mexican hospital: A pilot study. Transplantation Reports. 2023 Sep 1;8(3):100143.
Lyu CJ, Rha SY, Won SC. Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia. Yonsei medical journal. 2007 Apr 30;48(2):171-5.
Kaigler D, Krebsbach PH, Polverini PJ, Mooney DJ. Role of vascular endothelial growth factor in bone marrow stromal cell modulation of endothelial cells. Tissue engineering. 2003 Feb 1;9(1):95-103.
Salter AB, Meadows SK, Muramoto GG, Himburg H, Doan P, Daher P, Russell L, Chen B, Chao NJ, Chute JP. Endothelial progenitor cell infusion induces hematopoietic stem cell reconstitution in vivo. Blood, The Journal of the American Society of Hematology. 2009 Feb 26;113(9):2104-7.
Zheng X, Hua S, Zhao H, Gao Z, Cen D. Overexpression of hepatocyte growth factor protects chronic myeloid leukemia cells from apoptosis induced by etoposide. Oncology Letters. 2022 Apr 1;23(4):1-8.
Gwang Kim J, Kyun Sohn S, Hwan Kim D, Ho Baek J, Young Lee N, Soo Suh J, Chae SC, Soo Lee K, Bo Lee K. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leukemia & lymphoma. 2005 Jun 1;46(6):885-91.
Cerny-Reiterer S, Ghanim V, Hoermann G, Aichberger KJ, Herrmann H, Muellauer L, Repa A, Sillaber C, Walls AF, Mayerhofer M, Valent P. Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression. Neoplasia. 2012 Jul 1;14(7):572-IN10.
Zou X, Tang XY, Qu ZY, Sun ZW, Ji CF, Li YJ, Guo SD. Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review. International Journal of Biological Macromolecules. 2022 Mar 31;202:539-57.
Pandey P, Khan F, Upadhyay TK, Seungjoon M, Park MN, Kim B. New insights about the PDGF/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies. Biomedicine & Pharmacotherapy. 2023 May 1;161:114491.
Kalra K, Eberhard J, Farbehi N, Chong JJ, Xaymardan M. Role of PDGF-A/B ligands in cardiac repair after myocardial infarction. Frontiers in Cell and Developmental Biology. 2021 Aug 25;9:669188.
Cosnita AR, Raica M, Sava MP, Cimpean AM. Gene expression profile of vascular endothelial growth factors (VEGFs) and platelet-derived growth factors (PDGFs) in the normal cornea. in vivo. 2021 Mar 1;35(2):805-13.
Shree B, Das K, Sharma V. Emerging role of transforming growth factor-β-regulated long non-coding RNAs in prostate cancer pathogenesis. Cancer Pathogenesis and Therapy. 2023 Jul 1;1(3):195-204.
Ma W, Qin Y, Chapuy B, Lu C. LRRC33 is a novel binding and potential regulating protein of TGF-β1 function in human acute myeloid leukemia cells. PLoS One. 2019 Oct 10;14(10):e0213482.
Boye A. A cytokine in turmoil: Transforming growth factor beta in cancer. Biomedicine & Pharmacotherapy. 2021 Jul 1;139:111657.
Li C, Kuang K, Du J, Eymin B, Jia T. Far beyond anti-angiogenesis: Benefits for anti-basicFGF therapy in cancer. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2022 Jul 1;1869(7):119253.
Zahra FT, Sajib MS, Mikelis CM. Role of bFGF in acquired resistance upon anti-VEGF therapy in cancer. Cancers. 2021 Mar 20;13(6):1422.
Sajib S, Zahra FT, Lionakis MS, German NA, Mikelis CM. Mechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions. Angiogenesis. 2018 Feb;21:1-4.
Akwii RG, Sajib MS, Zahra FT, Mikelis CM. Role of angiopoietin-2 in vascular physiology and pathophysiology. Cells. 2019 May 17;8(5):471.
Yu P, Wilhelm K, Dubrac A, Tung JK, Alves TC, Fang JS, Xie Y, Zhu J, Chen Z, De Smet F, Zhang J. FGF-dependent metabolic control of vascular development. Nature. 2017 May 11;545(7653):224-8.
Jia T, Jacquet T, Dalonneau F, Coudert P, Vaganay E, Exbrayat-Héritier C, Vollaire J, Josserand V, Ruggiero F, Coll JL, Eymin B. FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells. BMC biology. 2021 Dec;19:1-26.
Farhat FS, Tfayli A, Fakhruddin N, Mahfouz R, Otrock ZK, Alameddine RS, Awada AH, Shamseddine A. Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Critical reviews in oncology/hematology. 2012 Nov 1;84(2):149-60
Le TB, Vu TC, Ho RZ, Prawira A, Wang L, Goh BC, Huynh H. Bevacizumab augments the antitumor efficacy of infigratinib in hepatocellular carcinoma. International journal of molecular sciences. 2020 Dec 10;21(24):9405.
Glenjen N, Mosevoll KA, Bruserud Ø. Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. International journal of cancer. 2002 Sep 1;101(1):86-94
Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S, Keating M, Freireich E. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, The Journal of the American Society of Hematology. 2000 Sep 15;96(6):2240-5.
Zhao MQ, Zhao HG. Serum level of angiogenesis-related cytokins in patients with myelodysplastic syndrome. Zhongguo shi yan xue ye xue za zhi. 2007 Jun 1;15(3):519-22.
Hong-bing H, Wen-yi X. Expression and clinical significance of serum VEGF and bFGF in children with acute leukemia. Xi bao yu fen zi Mian yi xue za zhi= Chinese Journal of Cellular and Molecular Immunology. 2011 Sep 1;27(9):1019-20.
Gwang Kim J, Kyun Sohn S, Hwan Kim D, Ho Baek J, Young Lee N, Soo Suh J, Chae SC, Soo Lee K, Bo Lee K. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leukemia & lymphoma. 2005 Jun 1;46(6):885-91.
Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends in pharmacological sciences. 2001 Apr 1;22(4):201-7.
Shah CA, Bei L, Wang H, Platanias LC, Eklund EA. The leukemia-associated Mll-Ell oncoprotein induces fibroblast growth factor 2 (Fgf2)-dependent cytokine hypersensitivity in myeloid progenitor cells. Journal of Biological Chemistry. 2013 Nov 8;288(45):32490-505.
Nara N, Kurokawa H, Tohda S, Tomiyama J, Nagata K, Tanikawa S. The effect of basic and acidic fibroblast growth factors (bFGF and aFGF) on the growth of leukemic blast progenitors in acute myelogenous leukemia. Experimental hematology. 1995 Aug 1;23(9):1030-4.
Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005 Aug 15;106(4):1154-63.
Menzel T, Rahman Z, Calleja E, White K, Wilson EL, Wieder R, Gabrilove J. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine.
Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood, The Journal of the American Society of Hematology. 2000 Dec 1;96(12):3712-8.
Dow JK, White RW. Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology. 2000 Jun 1;55(6):800-6.
Qin L, Zhao J, Wu Y, Zhao Y, Chen C, Xu M, Cheng J, Li C. Association between insulin-like growth factor 1 gene rs35767 polymorphisms and cancer risk: A meta-analysis. Medicine. 2019 Nov 1;98(46):e18017.
Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocrine reviews. 2008 Aug 1;29(5):535-59.
Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer. Nature clinical practice Oncology. 2007 Oct;4(10):591-602.
Yamada H, Iijima K, Tomita O, Taguchi T, Miharu M, Kobayashi K, Okita H, Saito M, Shimizu T, Kiyokawa N. Effects of insulin-like growth factor-1 on B-cell precursor acute lymphoblastic leukemia. International journal of hematology. 2013 Jan;97:73-82.
Naguib R, Abouegylah M, Sharkawy S, Fayed AA, Naguib H. Evaluation of serum levels of insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in patients with colorectal cancer: A case-control study. Cureus. 2021 Nov;13(11).
Kasprzak A, Adamek A. Insulin-like growth factor 2 (IGF2) signaling in colorectal cancer—from basic research to potential clinical applications. International journal of molecular sciences. 2019 Oct 3;20(19):4915.
Murphy N, Carreras-Torres R, Song M, Chan AT, Martin RM, Papadimitriou N, Dimou N, Tsilidis KK, Banbury B, Bradbury KE, Besevic J. Circulating levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 associate with risk of colorectal cancer based on serologic and mendelian randomization analyses. Gastroenterology. 2020 Apr 1;158(5):1300-12.
Adachi Y, Nojima M, Mori M, Matsunaga Y, Akutsu N, Sasaki S, Endo T, Kurozawa Y, Wakai K, Tamakoshi A, JACC Study. Insulin-like growth factor-related components and the risk of liver cancer in a nested case-control study. Tumor Biology. 2016 Nov;37:15125-32.
Najafabadi MM, Shamsasenjan K, Akbarzadehalaleh P. Angiogenesis status in patients with acute myeloid leukemia: from diagnosis to post-hematopoietic stem cell transplantation. International journal of organ transplantation medicine. 2017;8(2):57.
Richards MK, Goldin AB, Ehrlich PF, Beierle EA, Doski JJ, Goldfarb M, Langer M, Nuchtern JG, Vasudevan S, Gow KW. Partial nephrectomy for nephroblastoma: a national cancer data base review. The American Surgeon. 2018 Mar;84(3):338-43.
Liu XH, Zhang CM, Pan PQ, Zhang DQ, Huang X, Ji ZH. Long noncoding RNA KCNQ1OT1 contributes to the development of nephroblastoma via modulating miR-21/PTEN axis. Journal of Biological Regulators and Homeostatic Agents. 2020 Sep 1;34(5):1901-8.
Liao W, Zhu J, Zhang H, Cui Y, Peng Q. The relationship between vascular endothelial growth factor expression and the risk of childhood nephroblastoma: systematic review and meta-analysis. Translational Pediatrics. 2022 Mar;11(3):375.
Qi Q, Geng Y, Sun M, Wang P, Chen Z. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer. Pancreatology. 2015 Mar 1;15(2):145-50.
Hang J, Xue P, Yang H, Li S, Chen D, Zhu L, Huang W, Ren S, Zhu Y, Wang L. Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. Scientific Reports. 2017 Jun 7;7(1):2993.
Sellers CM, Uhlig J, Ludwig JM, Stein SM, Kim HS. Inflammatory markers in intrahepatic cholangiocarcinoma: Effects of advanced liver disease. Cancer medicine. 2019 Oct;8(13):5916-29.
Hoshimoto S, Hishinuma S, Shirakawa H, Tomikawa M, Ozawa I, Ogata Y. Association of preoperative platelet-to-lymphocyte ratio with poor outcome in patients with distal cholangiocarcinoma. Oncology. 2019 Jun 5;96(6):290-8.
Zhu S, Yang J, Cui X, Zhao Y, Tao Z, Xia F, Chen L, Huang J, Ma X. Preoperative platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as predictors of clinical outcome in patients with gallbladder cancer. Scientific reports. 2019 Feb 12;9(1):1823.
Fu J, Su X, Li Z, Deng L, Liu X, Feng X, Peng J. HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene. 2021 Jul 15;40(28):4625-51.
Moosavi F, Giovannetti E, Saso L, Firuzi O. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Critical reviews in clinical laboratory sciences. 2019 Nov 17;56(8):533-66.
Maroun CR, Rowlands T. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacology & therapeutics. 2014 Jun 1;142(3):316-38.
Mantovani A, Ponzetta A, Inforzato A, Jaillon S. Innate immunity, inflammation and tumour progression: double‐edged swords. Journal of internal medicine. 2019 May;285(5):524-32.
Zhang K, Hua YQ, Wang D, Chen LY, Wu CJ, Chen Z, Liu LM, Chen H. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. Journal of translational medicine. 2019 Dec;17:1-8.
Ünek İT, Öztop İ, Başbınar Y, Ünek T, Leblebici A, Çakıroğlu E, Uysal T, Akagündüz B, Ellidokuz H, Astarcıoğlu İ. Association of Serum Hepatocyte Growth Factor Level with Systemic Inflammatory Biomarkers in Patients with Pancreatobiliary Cancer. The Turkish Journal of Gastroenterology. 2023 May;34(5):568.
Modica C, Tortarolo D, Comoglio PM, Basilico C, Vigna E. MET/HGF co-targeting in pancreatic cancer: a tool to provide insight into the tumor/stroma crosstalk. International journal of molecular sciences. 2018 Dec 7;19(12):3920.
Yang J, Liu X, Nyland SB, Zhang R, Ryland LK, Broeg K, Baab KT, Jarbadan NR, Irby R, Loughran Jr TP. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood, The Journal of the American Society of Hematology. 2010 Jan 7;115(1):51-60.
Wang Z, Kong D, Banerjee S, Li Y, Adsay NV, Abbruzzese J, Sarkar FH. Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-κB signaling. Cancer research. 2007 Dec 1;67(23):11377-85.
Ustach CV, Taube ME, Hurst Jr NJ, Bhagat S, Bonfil RD, Cher ML, Schuger L, Kim HR. A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer research. 2004 Mar 1;64(5):1722-9.
Xu L, Tong R, Cochran DM, Jain RK. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor β signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer research. 2005 Jul 1;65(13):5711-9.
Kong D, Banerjee S, Huang W, Li Y, Wang Z, Kim HR, Sarkar FH. Mammalian target of rapamycin repression by 3, 3′-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D–overexpressing PC3 cells. Cancer research. 2008 Mar 15;68(6):1927-34.
Rodríguez TM, Saldías A, Irigo M, Zamora JV, Perone MJ, Dewey RA. Effect of TGF-β1 stimulation on the secretome of human adipose-derived mesenchymal stromal cells. Stem cells translational medicine. 2015 Aug 1;4(8):894-8.
del Pozo Martin Y, Park D, Ramachandran A, Ombrato L, Calvo F, Chakravarty P, Spencer-Dene B, Derzsi S, Hill CS, Sahai E, Malanchi I. Mesenchymal cancer cell-stroma crosstalk promotes niche activation, epithelial reversion, and metastatic colonization. Cell reports. 2015 Dec 22;13(11):2456-69.
Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?. Cell stem cell. 2015 Mar 5;16(3):225-38.
Sakaguchi AY, Amarante MK, Oliveira CECd HC, Trigo FC WM. Transforming growth factor beta 1: Possible involvement with acute lymphoblastic leukemia prognosis in pediatric patients. Clin Oncol Res. 2020;6(10.31487).
Vaidya A, Kale VP. TGF-β signaling and its role in the regulation of hematopoietic stem cells. Systems and synthetic biology. 2015 Jun;9:1-0.
Blank U, Karlsson S. TGF-β signaling in the control of hematopoietic stem cells. Blood, The Journal of the American Society of Hematology. 2015 Jun 4;125(23):3542-50.
Al-Mowallad A, Carr T, Al-Qouzi A, Li C, Byers R, Kumar S. Plasma CD105, TGFβ-1, TGFβ-3 and the Ligand/Receptor Complexes in Children with Acute Lymphoblastic Leukaemia. Anticancer research. 2006 Jan 1;26(1B):543-7.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
